CenExel Announces Formation of Task Forces to Advance Patient-Focused Clinical Research

DRAPER, UTAH / ACCESS Newswire / October 16, 2025 / CenExel, a leading, wholly owned clinical research site network, announces the formation of the CenExel Task Forces, designed to strengthen collaboration, enhance scientific innovation, and further elevate patient care across its nationwide network.

The new CenExel Task Forces, which are focused on Psychiatry, Pain, and Metabolic research, unite key opinion leaders and operational experts from across CenExel’s nineteen Centers of Excellence to advance clinical research through shared expertise, strategic alignment, and collaboration.

Task Force Leadership

These therapeutic task forces will drive CenExel’s mission to put patients first by optimizing trial design and delivery, ensuring access to innovative therapies, and reinforcing consistency and quality across the network. The initiative also strengthens the partnership between scientific and operational leaders, enabling CenExel to provide sponsors and CROs with even greater data quality and reliability.

“Our leadership team is the backbone of CenExel,” said Ryan Brooks, CenExel’s Chief Executive Officer. “These new Task Forces harness the collective expertise and compassion of our most experienced clinicians and researchers. By bringing them together to share insights and align strategy, we’re ensuring that every decision – scientific, operational, and commercial – ultimately support the patients in our communities who trust us with their care.”

In conjunction with the Task Force initiative, CenExel also announced several leadership appointments that reflect the company’s continued investment in operational excellence and scientific depth:

The Task Forces will convene regularly to align scientific and operational priorities: monthly full-team meetings to share strategy and insights, biweekly subgroup sessions to focus on therapeutic or functional areas, and quarterly reviews with executive leadership to guide network-wide growth and innovation.

CenExel’s establishment of these Task Forces reflects its ongoing commitment to advancing clinical research with a patient-first mindset by combining scientific rigor, compassionate care, and deep community engagement to deliver meaningful breakthroughs for patients and their families.

Contact Information
Sara Koeblin
Director of Corporate Communications
s.koeblin@cenexel.com
(617) 639-6075

SOURCE: CenExel Research

View the original press release on ACCESS Newswire

Staff

Recent Posts

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

4 hours ago

Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/…

5 hours ago

Equinox Integrates Oura Ring Data Into EQX ARC, New Women’s Health & Performance Program

NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Equinox, the authority in high-performance luxury lifestyle, announced that…

5 hours ago

Patient Engagement Solutions Market worth $51.69 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., Jan. 16, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Patient Engagement Solutions Market…

5 hours ago

From Awareness to Action: Linus Health Drives the Next Era of Early Brain Health Detection

Expanding adoption, evidence, and innovation to support earlier identification and intervention across care and researchBOSTON,…

5 hours ago